Cargando…

P829: GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Schilhabel, Anke, Khouja, Mouhamad, Stewart, Peter, Strifler, Susanne, Stuebig, Thomas, Kull, Miriam, Baldus, Claudia, Pott, Christiane, Gonzalez de Castro, David, Engelhardt, Monika, Krönke, Jan, Einsele, Hermann, Knop, Stefan, Brüggemann, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431086/ http://dx.doi.org/10.1097/01.HS9.0000970220.07708.6d

Ejemplares similares

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
por: Danhof, Sophia, et al.
Publicado: (2015)

Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells
por: Kotrova, Michaela, et al.
Publicado: (2021)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

S189: PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA
por: Ramberger, Evelyn, et al.
Publicado: (2023)

Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
por: Geis, Maria, et al.
Publicado: (2021)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
por: Hose, Dorothea, et al.
Publicado: (2020)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
por: Keppler, Sarah, et al.
Publicado: (2016)

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
por: Engelhardt, Monika, et al.
Publicado: (2020)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Lomefloxacin Induces Oxidative Stress and Apoptosis in COLO829 Melanoma Cells
por: Beberok, Artur, et al.
Publicado: (2017)

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
por: Fischer, Julia, et al.
Publicado: (2022)

829. Identification of Congenital Cytomegalovirus Infection Using Real-World Healthcare Data
por: Weil, Clara, et al.
Publicado: (2020)

829 Utility of universal COVID-19 testing in a midwest pregnant population
por: Forde, Braxton, et al.
Publicado: (2021)

Effect of juglone on C-32 and COLO 829 melanoma cells in in vitro cultures
por: Zielińska, Aleksandra, et al.
Publicado: (2022)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

The utility of cfDNA in TGCT patient management: a systematic review
por: Krasic, Jure, et al.
Publicado: (2022)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Partitas No. 5, BWV 829 [G major], No. 6 BWV 830 [E minor]
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1993)

829 Highly Drug-Resistant Non-Typhoidal Salmonella in the United States, 1996–2012
por: Reynolds, Jared, et al.
Publicado: (2014)

Epidemiological pattern of maxillofacial fractures in northern China: A retrospective study of 829 cases
por: Xiao-Dong, Liu, et al.
Publicado: (2020)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker
por: Škara, Lucija, et al.
Publicado: (2023)

Propuesta de reforma al artículo 829 de la ley federal del trabajo.
por: Pérez Núñez, Víctor
Publicado: (1995)

Purification and characterization of the enzymes involved in nicotinamide adenine dinucleotide degradation by Penicillium brevicompactum NRC 829
por: Ali, Thanaa Hamed, et al.
Publicado: (2016)

High-Throughput, Amplicon-Based Sequencing of the CREBBP Gene as a Tool to Develop a Universal Platform-Independent Assay
por: Fuellgrabe, Marc W., et al.
Publicado: (2015)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
por: Lubbers, Bart R., et al.
Publicado: (2021)

829. Incidence of Low BMD and Barriers to Routine Screening for Osteoporosis in HIV Patients in Eastern North Carolina
por: Rajput, Smit, et al.
Publicado: (2021)

P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS
por: Martijn Kolijn, Pieter, et al.
Publicado: (2023)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience
por: Ludwig, Heinz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ckoucdlnja4djcnih5r88gpfih